COCH EBITDA | ENVOY MEDICAL, INC.

ENVOY MEDICAL, INC. (COCH) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.57M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.96M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$5.71M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$5.07M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$5.57M	(m)	(m)	(m)	(m)	-$5.46M*	$278.00K	$3.13M	(m)	(m)
2026-03-31	Reported	(m)	-$5.96M	(m)	(m)	(m)	(m)	-$6.06M	$313.00K	$3.64M	(m)	(m)
2025-09-30	Reported	(m)	-$5.71M	(m)	(m)	(m)	$0.00*	-$4.33M*	$203.00K	$2.70M	(m)	(m)
2025-06-30	Reported	(m)	-$5.07M	(m)	(m)	(m)	$1.00K*	-$4.46M*	$234.00K	$2.48M	(m)	(m)
2025-03-31	Reported	(m)	-$5.11M	(m)	(m)	(m)	$6.00K	-$3.73M	$226.00K	$2.75M	(m)	(m)
2024-09-30	Reported	(m)	-$4.97M	(m)	(m)	(m)	$1.16M*	-$2.62M*	$187.00K	$2.76M	(m)	(m)
2024-06-30	Reported	(m)	-$4.85M	(m)	(m)	(m)	(m)	-$4.65M*	$245.00K	$2.59M	(m)	(m)
2024-03-31	Reported	(m)	-$4.88M	(m)	(m)	(m)	(m)	-$5.59M	$153.00K	$2.36M	(m)	(m)
2023-09-30	Reported	(m)	-$3.38M	(m)	(m)	(m)	$62.00K*	$1.10M*	$189.00K	$1.85M	$1.43M	(m)
2023-06-30	Reported	(m)	-$4.48M	(m)	(m)	(m)	$11.00K*	-$4.03M*	$162.00K	$2.15M	(m)	$121.25K
2023-03-31	Reported	(m)	-$3.77M	(m)	(m)	(m)	$59.00K	-$3.01M	$175.00K	$1.93M	(m)	$841.52K
2022-09-30	Reported	(m)	-$1.80M	(m)	(m)	(m)	(m)	-$5.25M*	$106.00K	$935.00K	$812.00K	$533.96K
2022-06-30	Reported	(m)	-$901.36K	(m)	(m)	(m)	(m)	-$400.16K*	(m)	(m)	(m)	$108.31K
2022-03-31	Reported	(m)	-$1.49M	(m)	(m)	(m)	(m)	-$772.74K	(m)	(m)	(m)	$0.00
2021-09-30	Reported	(m)	-$2.99M	(m)	(m)	(m)	(m)	-$701.35K*	(m)	(m)	(m)	$0.00
2021-06-30	Reported	(m)	-$1.07M	(m)	(m)	(m)	(m)	-$405.32K*	(m)	(m)	(m)	$0.00
2021-03-31	Reported	(m)	-$966.28K	(m)	(m)	(m)	(m)	-$1.25M	(m)	(m)	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$22.27M	(m)	(m)	(m)	$179.00K	-$18.20M	$874.00K	$12.49M	(m)	(m)
2024-12-31	Reported	(m)	-$19.26M	(m)	(m)	(m)	$980.00K	-$17.95M	$742.00K	$10.18M	(m)	(m)
2023-12-31	Reported	(m)	-$18.36M	(m)	(m)	(m)	$153.00K	-$17.09M	$789.00K	$8.96M	$7.28M	(m)
2022-12-31	Reported	(m)	-$8.71M	(m)	(m)	(m)	$218.00K	-$8.80M	$498.00K	$4.97M	$2.58M	$1.50M
2021-12-31	Reported	(m)	-$5.20M	(m)	(m)	(m)	(m)	-$3.24M	(m)	(m)	(m)	(m)

Stock Name	Country	Market Cap	PE Ratio
ALPHA PRO TECH LTD (APT)		$0.052B	13.63
MYOMO, INC. (MYO)	United States	$0.065B	-2.85
MILESTONE SCIENTIFIC INC. (MLSS)	United States	$0.036B	-6.85
Safe Pro Group Inc. (SPAI)	United States	$0.090B
Lifeward Ltd. (LFWD)		$0.021B
ENvue Medical, Inc. (FEED)	United States	$0.011B
LAKELAND INDUSTRIES INC (LAKE)	United States	$0.104B	-4.21
NutriBand Inc. (NTRB)	United States	$0.109B
Bone Biologics Corp (BBLG)	United States	$0.001B
Conexeu Sciences Inc. (CNXU)	United States	$0.111B